Key Points
- Director Michel Revel bought 54,545 shares of NLS Pharmaceutics (NASDA: NCEL) on April 27 at $2.75 per share for about $149,999, increasing his stake by 6.04 to 957,530 shares (valued ~ $2.63M); the purchase was reported in an SEC filing.
- Stock and company context: NCEL opened at $3.42, with a one-year range of $1.83–$30.80 and 50- and 200-day SMAs of $2.73 and $4.04 respectively; NLS is a clinical-stage biopharma developing controlled-release melatonin receptor agonists for circadian and rare sleep disorders.
NLS Pharmaceutics Ltd. (NASDAQ:NCEL - Get Free Report) Director Michel Revel acquired 54,545 shares of the stock in a transaction on Monday, April 27th. The stock was bought at an average price of $2.75 per share, with a total value of $149,998.75. Following the completion of the acquisition, the director directly owned 957,530 shares of the company's stock, valued at $2,633,207.50. This trade represents a 6.04% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.
NLS Pharmaceutics Stock Performance
Shares of NCEL opened at $3.42 on Thursday. NLS Pharmaceutics Ltd. has a one year low of $1.83 and a one year high of $30.80. The company has a 50-day simple moving average of $2.73 and a two-hundred day simple moving average of $4.04.
About NLS Pharmaceutics
(
Get Free Report)
NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.
The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
